Enrollment has begun
for a study testing the safety and effectiveness of the experimental
drug MBP8298 (BioMS Medical Corp.) in 510 people with
secondary-progressive multiple sclerosis. Up to 60 sites nationwide
will be enrolling patients by September. This drug is administered
intravenously (into the vein) every 6 months.
Trial enrollment info here